Teladoc HealthNYSE: TDOC

Spoiler: The news isn't pretty.

Where Will Teladoc Be in 5 Years?

This telehealth leader has a lot of work to do.

Hint: You won't find it on the top or bottom lines.

Teladoc Health, Inc. (NYSE:TDOC ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Michael Minchak - Head of Investor Relations Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Conference Call Participants Stephanie Davis - Barclays Lisa Gill - JPMorgan Jessica Tassan - Piper Sandler Michael Cherny - Leerink Partners Sean Dodge - RBC Capital Markets Sarah James - Cantor Fitzgerald Jailendra Singh - Truist Securities Richard Close - Cannacord Glen Santangelo - Jefferies Charles Rhyee - TD Cowen Allen Lutz - Bank of America Sameer Patel - Evercore ISI Operator Hello, and welcome to the Teladoc Health Third Quarter 2024 Call. My name is Alex, and I'll be coordinating the call today.

Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Teladoc (TDOC) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago.

The latest trading day saw Teladoc (TDOC) settling at $8.60, representing a -0.92% change from its previous close.

Teladoc Health, Inc. shows signs of bottoming out after withdrawing guidance due to customer acquisition issues, particularly in the BetterHelp division. The new CEO must drive product innovation to capitalize on growth opportunities in weight loss management and chronic care management. The stock is trading at a deep valuation, around 5x EBITDA targets, providing a potential investment opportunity despite current challenges.